Lack of significant de novo HLA allosensitization in ventricular assist device recipients transfused with leukoreduced, ABO identical blood products

Human Immunology

Volumn 70, Issue 6, 2009, Pages 413-416

  Coppage, Myra ^a   Baker, Marc ^b   Fialkow, Lawrence ^a   Meehan, Danielle ^a   Gettings, Kelly ^a   Chen, Leway ^b   Massey, H Todd ^b   Blumberg, Neil ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b STRONG MEMORIAL HOSPITAL   (United States)

Author keywords

ABO matching; Allosensitization; PRA; WBC reduction

Indexed keywords

HLA ANTIBODY; HLA ANTIGEN;

ADULT; AGED; ALLOIMMUNITY; ANTIBODY DETECTION; ARTICLE; BLOOD COMPATIBILITY; BLOOD GROUP ABO SYSTEM; BLOOD TRANSFUSION; FEMALE; HEART ASSIST DEVICE; HEART TRANSPLANTATION; HUMAN; IRRADIATION; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION;

ABO BLOOD-GROUP SYSTEM; ADULT; AGED; BLOOD TRANSFUSION; FEMALE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HLA ANTIGENS; HUMANS; ISOANTIBODIES; LEUKOCYTE REDUCTION PROCEDURES; LEUKOCYTES; MALE; MIDDLE AGED;

EID: 67349242994     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.03.001     Document Type: Article

References (38)

1. Kirklin J.K., and Holman W.L. Mechanical circulatory support therapy as a bridge to transplant or recovery (new advances). Curr Opin Cardiol 21 (2006) 120-126
2. Marcel R., and Meyer D.M. An overview of approved and investigational left ventricular assist devices. Proc Bayl Univ Med Cent 17 (2004) 407-410
3. Hampton C.R., and Verrier E.D. Systemic consequences of ventricular assist devices: Alterations of coagulation, immune function, inflammation, and the neuroendocrine system. Artif Organs 26 (2002) 902-908
4. Rothenburger M., Wilhelm M., Hammel D., Schmid C., Plenz G., Tjan T.D.T., Baba H., et al. Immune response in the early postoperative period after implantation of a left-ventricular assist device system. Transplant Proc 33 (2001) 1955-1957
5. Ankersmit H.J., Edwards N.M., Schuster M., John R., Kocher A., Rose E.A., et al. Quantitative changes in T-cell populations after left ventricular assist device implantation: Relationship to T-cell apoptosis and soluble CD95. Circulation 100 19 Suppl (1999) II211-II215
6. Itescu S., Schuster M., Burke E., Ankersmit J., Kocher A., Deng M., et al. Immunobiologic consequences of assist devices. Cardiol Clin 21 (2003) 119-133
7. Moazami N., Itescu S., Williams M.R., Argenziano M., Weinberg A., and Oz M.C. Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support. J Heart Lung Transplant 17 (1998) 876-880
8. Massad M.G., Cook D.J., Schmitt S.K., Smedira N.G., McCarthy J.F., Vargo R.L., and McCarthy P.M. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg 64 (1997) 1120-1125
9. Karpinski M., Pochinco D., Dembinski I., Laidlaw W., Zacharias J., and Nickerson P. Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates. J Am Soc Nephrol 15 (2004) 818-824
10. Gonzalez-Stawinski G.V., Atik F.A., McCarthy P.M., Roselli E.E., Hoercher K., Navia J.L., et al. Early and late rejection and HLA sensitization at the time of heart transplantation in patients bridged with left ventricular assist devices. Transplant Proc 37 (2005) 1349-1351
11. Kerman R.H., Radovancevic B., Przybylowski P., Frazier O.H., Thomas C., and Kahan B.D. LVAD treated heart recipients do not have deleterious HLA antibody. J Heart Lung Transplant 20 (2001) 211
12. Newell H., Smith J.D., Rogers P., Birks E., Danskine A.J., Fawson R.E., and Rose M.L. Sensitization following LVAD implantation using leucodepleted blood is not due to HLA antibodies. Am J Transplant 6 (2006) 1712-1717
13. Pamboukian S.V., Costanzo M.R., Dunlap S., Rayburn B., Westfall A.O., You Z.Y., et al. Relationship between bridging with ventricular assist device on rejection after heart transplantation. J Heart Lung Transplant 24 (2005) 310-315
14. Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 337 (1997) 1861-1869
15. Blumberg N., Heal J.M., Kirkley S.A., DiPersio J.F., Rapoport A.P., and Rowe J.M. Leukodepleted-ABO-identical blood components in the treatment of hematologic malignancies: A cost analysis. Am J Hematol 48 (1995) 108-115
16. Blumberg N., Heal J.M., and Gettings K.F. WBC reduction of RBC transfusions is associated with a decreased incidence of RBC alloimmunization. Transfusion 43 (2003) 945-952
17. Blumberg N., Heal J.M., Hicks Jr. G.L., and Risher W.H. Association of ABO-mismatched platelet transfusions with morbidity and mortality in cardiac surgery. Transfusion 41 (2001) 790-793
18. Vaidya S., Cooper T.Y., Avandsalehi J., Barnes T., Brooks K., Hymel P., et al. Improved flow cytometric detection of HLA alloantibodies using pronase: Potential implications in renal transplantation. Transplantation 71 (2001) 422-428
19. Grinda J.M., Bricourt M.O., Amrein C., Salvi S., Guillemain R., Francois A., et al. Human leukocyte antigen sensitization in ventricular assist device recipients: A lesser risk with the DeBakey axial pump. Ann Thorac Surg 80 (2005) 945-948
20. Baran D.A., Gass A.L., Galin I.D., Zucker M.J., Arroyo L.H., Goldstein D.J., et al. Lack of sensitization and equivalent post-transplant outcomes with the Novacor left ventricular assist device. J Heart Lung Transplant 24 (2005) 1886-1890
21. George I., Colley P., Russo M.J., Martens T.P., Burke E., Oz M.C., et al. Association of device surface and biomaterials with immunologic sensitization after mechanical support. J Thorac Cardiovasc Surg 135 (2008) 1372-1379
22. Pagani F.D., Dyke D.B., Wright S., Cody R., and Aaronson K.D. Development of anti-major histocompatibility complex class I or II antibodies following left ventricular assist device implantation: Effects on subsequent allograft rejection and survival. J Heart Lung Transplant 20 (2001) 646-653
23. Rossini A.A., Mordes J.P., Greiner D.L., Nakano K., Appel M.C., and Handler E.S. Spleen cell transfusion in the Bio-Breeding/Worcester rat. Prevention of diabetes, major histocompatibility complex restriction, and long-term persistence of transfused cells. J Clin Invest 77 (1986) 1399-1401
24. Blumberg N., and Heal J.M. Blood transfusion immunomodulation: The silent epidemic. Arch Pathol Lab Med 122 (1998) 117-119
25. Blumberg N. Deleterious clinical effects of transfusion immunomodulation: Proven beyond a reasonable doubt. Transfusion 45 2 Suppl (2005) S33-S39
26. Oh J.H., McClure H.M., and Galvao M.M. Comparison of immunogenicity of fresh and stored blood. A study in rhesus monkeys. Transplantation 33 (1982) 198-200
27. Claas F.H., Roelen D.L., van Rood J.J., and Brand A. Modulation of the alloimmune response by blood transfusions. Transfus Clin Biol 8 (2001) 315-317
28. Blajchman M.A., Dzik S., Vamvakas E.C., Sweeney J., and Snyder E.L. Clinical and molecular basis of transfusion-induced immunomodulation: Summary of the proceedings of a state-of-the-art conference. Transfus Med Rev 15 (2001) 108-135
29. Goldman J., Liesveld J., Nichols D., Heal J., and Blumberg N. ABO incompatibility between donor and recipient and clinical outcomes in allogeneic stem cell transplantation. Leuk Res 27 (2003) 489-491
30. Heal J.M., Kenmotsu N., Rowe J.M., and Blumberg N. A possible survival advantage in adults with acute leukemia receiving ABO-identical platelet transfusions. Am J Hematol 45 (1994) 189-190
31. van Marwijk Kooy M., van Prooijen H.C., Moes M., Bosma-Stants I., and Akkerman J.W. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: A prospective, randomized trial. Blood 77 (1991) 201-205
32. Blumberg N., Gettings K.F., Turner C., Heal J.M., and Phipps R.P. An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions. Transfusion 46 (2006) 1813-1821
33. Kaufman J., Spinelli S.L., Schultz E., Blumberg N., and Phipps R.P. Release of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusion. J Thromb Haemost 5 (2007) 788-796
34. Khan S.Y., Kelher M.R., Heal J.M., Blumberg N., Boshkov L.K., Phipps R., et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood 108 (2006) 2455-2462
35. Rothenburger M., Wilhelm M., Hammel D., Schmid C., Plenz G., Tjan T.D., et al. Immune response in the early postoperative period after implantation of a left-ventricular assist device system. Transplant Proc 33 (2001) 1955-1957
36. Itescu S., and John R. Interactions between the recipient immune system and the left ventricular assist device surface: Immunological and clinical implications. Ann Thorac Surg 75 6 Suppl (2003) S58-S65
37. Heal J.M., Masel D., and Blumberg N. Interaction of platelet fc and complement receptors with circulating immune complexes involving the AB0 system. Vox Sang 71 (1996) 205-211
38. Heal J.M., Masel D., Rowe J.M., and Blumberg N. Circulating immune complexes involving the ABO system after platelet transfusion. Br J Haematol 85 (1993) 566-572